Summary
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline
Protara Therapeutics is rated Buy, with a risk-adjusted fair value of $9.96 per share versus the current ~$4 price. TARA-002 targets NMIBC and Lymphatic Malformations; orphan drug indications offer significant upside, despite NMIBC's competitive landscape and lower CR rates. IV Choline Chloride, targeting severe choline deficiency in parenteral nutrition patients, could generate substantial revenue if approved, with pivotal data expected in 2026.
What Makes Protara Therapeutics (TARA) a New Buy Stock
Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript
Protara Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 43 | $224.12 | $168.56 | -$55.56 | -24.79% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 11,000 | $42,020 | $45,320 | $3,300 | 7.85% |
| BG Bart Gancher Intech Investment Management LLC | 13,562 | $41,092.86 | $55,875.44 | $14,782.58 | 35.97% |
 John H. Burbank III Passport Capital LLC | 971,614 | $8.87M | $3.86M | -$5.02M | -56.53% |
 Point72 Asset Management LP Point72 Asset Management LP | 548,932 | $2.86M | $2.18M | -$680,675.73 | -23.8% |
Protara Therapeutics Inc. (TARA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Protara Therapeutics Inc. ever had a stock split?
Protara Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jesse Shefferman CEO | NASDAQ (NMS) Exchange | 74365U107 CUSIP |
| US Country | 46 Employees | 10 Jan 2020 Last Dividend | 10 Jan 2020 Last Split | 22 Oct 2014 IPO Date |
Overview
Protara Therapeutics, Inc. is a pioneering force in the biopharmaceutical industry, focusing its efforts on the development of game-changing therapies aimed at treating cancer and rare diseases. Originally known as ArTara Therapeutics, Inc., the company underwent a rebranding in May 2020 and adopted its current name. With its headquarters in New York, New York, Protara is committed to pushing the boundaries of medicine through its clinical-stage programs. Its primary mission is to offer new hope and solutions to patients facing the challenges of lymphatic malformations and intestinal failure-associated liver disease.
Products and Services
- TARA-002: An investigational cell therapy developed by Protara Therapeutics. It is at the forefront of the company's research and is designed specifically for treating lymphatic malformations, a condition that can cause significant morbidity and impact the quality of life. This therapy represents a key example of Protara's commitment to addressing unmet medical needs through innovative treatments.
- Intravenous Choline Chloride: This investigational therapy is another example of Protara's dedication to rare diseases, specifically targeting intestinal failure associated liver disease (IFALD). IFALD is a critical condition that can arise from chronic intestinal failure, and Protara's development of intravenous choline chloride is aimed at providing a phospholipid substrate replacement therapy to address the underlying issues of this disease.
